Press Releases May 20, 2026 04:05 PM

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

CeriBell announces participation in William Blair Growth Stock Conference with CEO presentation

By Maya Rios CBLL

CeriBell, Inc., a medical technology company specializing in rapid diagnosis and management of serious neurological conditions, announced that CEO Jane Chao will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The company showcased its Ceribell System, an FDA-cleared, AI-powered EEG platform designed for acute-care settings, enabling rapid detection of seizures and delirium in critical care patients.

Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
CBLL

Key Points

  • CeriBell will present at a major growth stock conference, increasing investor visibility.
  • The company’s Ceribell System is FDA-cleared and combines portable hardware with AI to diagnose neurological conditions rapidly in acute care settings.
  • The presentation will be webcast live, enhancing accessibility for investors and stakeholders.

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.

Event: William Blair 46th Annual Growth Stock Conference
Date: Wednesday, June 3, 2026
Time: 9:20 a.m. PDT / 11:20 a.m. CDT

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detection of seizure and delirium in patients in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston
Gilmartin Group
[email protected] 

Media Contact
Brian Price
[email protected]


Risks

  • Market adoption and commercial success of Ceribell System depend on hospital integrations and reimbursement policies, which may introduce uncertainty.
  • Competition in the medical technology sector for neurological diagnostics is intense, potentially impacting Ceribell's market share.
  • Regulatory and clinical validation risks remain inherent to medical device companies, affecting future product approvals and updates.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026